Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/25786
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBailey, DP-
dc.contributor.authorKilbride, C-
dc.contributor.authorHarper, JH-
dc.contributor.authorVictor, C-
dc.contributor.authorBrierley, ML-
dc.contributor.authorHewson, DJ-
dc.contributor.authorChater, AM-
dc.date.accessioned2023-01-16T11:13:08Z-
dc.date.available2023-01-16T11:13:08Z-
dc.date.issued2023-01-07-
dc.identifierORCID iDs: Daniel P. Bailey https://orcid.org/0000-0003-3772-630X; Cherry Kilbride https://orcid.org/0000-0002-2045-1883; Christina Victor https://orcid.org/0000-0002-4213-3974; Marsha L. Brierley https://orcid.org/0000-0002-6806-6052.-
dc.identifier1-
dc.identifier.citationBailey, D.P. et al. (2023) 'The Frail-LESS (LEss Sitting and Sarcopenia in Frail older adults) intervention to improve sarcopenia and maintain independent living via reductions in prolonged sitting: a randomised controlled feasibility trial protocol', Pilot Feasibility Studies 9, 1, pp.1 - 12. doi: 10.1186/s40814-022-01225-7.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/25786-
dc.descriptionAvailability of data and materials: Not applicable.-
dc.description.abstractCopyright © The Author(s) 2023. Background: Sarcopenia is a progressive and generalised loss of muscle mass and function with advancing age and is a major contributor to frailty. These conditions lead to functional disability, loss of independence, and lower quality of life. Sedentary behaviour is adversely associated with sarcopenia and frailty. Reducing and breaking up sitting should thus be explored as an intervention target for their management. The primary aim of this study, therefore, is to examine the feasibility, safety, and acceptability of conducting a randomised controlled trial (RCT) that evaluates a remotely delivered intervention to improve sarcopenia and independent living via reducing and breaking up sitting in frail older adults. Methods: This mixed-methods randomised controlled feasibility trial will recruit 60 community-dwelling older adults aged ≥ 65 years with very mild or mild frailty. After baseline measures, participants will be randomised to receive the Frail-LESS (LEss Sitting and Sarcopenia in Frail older adults) intervention or serve as controls (usual care) for 6 months. Frail-LESS is a remotely delivered intervention comprising of tailored feedback on sitting, information on the health risks of excess sitting, supported goal setting and action planning, a wearable device that tracks inactive time and provides alerts to move, health coaching, and peer support. Feasibility will be assessed in terms of recruitment, retention and data completion rates. A process evaluation will assess intervention acceptability, safety, and fidelity of the trial. The following measures will be taken at baseline, 3 months, and 6 months: sitting, standing, and stepping using a thigh-worn activPAL4 device, sarcopenia (via hand grip strength, muscle mass, and physical function), mood, wellbeing, and quality of life. Discussion: This study will determine the feasibility, safety, and acceptability of evaluating a remote intervention to reduce and break up sitting to support improvements in sarcopenia and independent living in frail older adults. A future definitive RCT to determine intervention effectiveness will be informed by the study findings. Trial registration: ISRCTN, ISRCTN17158017; Registered 6 August 2021, https://www.isrctn.com/ISRCTN17158017.en_US
dc.description.sponsorshipAbbeyfield Research Foundationen_US
dc.format.extent1 - 12-
dc.format.mediumElectronic-
dc.publisherBioMed Centralen_US
dc.rightsCopyright © The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectsarcopeniaen_US
dc.subjectfrailtyen_US
dc.subjectsedentary behaviouren_US
dc.subjectprolonged sittingen_US
dc.subjectbehaviour changeen_US
dc.subjectactivPALen_US
dc.titleThe Frail-LESS (LEss Sitting and Sarcopenia in Frail older adults) intervention to improve sarcopenia and maintain independent living via reductions in prolonged sitting: A randomised controlled feasibility trial protocolen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1186/s40814-022-01225-7-
dc.relation.isPartOfPilot and Feasibility Studies-
pubs.publication-statusPublished-
dc.identifier.eissn2055-5784-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data1.19 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons